Publication

Immunomodulatory Low-Dose Whole-Lung Radiation for Patients with COVID-19-Related Pneumonia

Downloadable Content

Persistent URL
Last modified
  • 05/15/2025
Type of Material
Authors
    C.B. Hess, Emory UniversityZachary Buchwald, Emory UniversityWilliam Stokes, Emory UniversityT. Nasti, Emory UniversityJeffrey Switchenko, Emory UniversityBrent Weinberg, Emory UniversityNadine Rouphael, Emory UniversityJames Steinberg, Emory UniversityKaren Godette, Emory UniversityDavid Murphy, Emory UniversityRafi Ahmed, Emory UniversityWalter Curran Jr, Emory UniversityMohammad Khan, Emory University
Language
  • English
Date
  • 2020-12-01
Publisher
  • Elsevier
Publication Version
Copyright Statement
  • © 2020 Published by Elsevier Inc.
Final Published Version (URL)
Title of Journal or Parent Work
Volume
  • 108
Issue
  • 5
Abstract
  • Phase I clinical trials have established that low-dose, whole-lung radiotherapy (LD-RT) is safe for patients with COVID-19-related pneumonia. By focally dampening cytokine hyperactivation, LD-RT may improve COVID-19 outcomes through immunomodulation.
Author Notes
  • Author Disclosure:C.B. Hess: Patent/License Fees/Copyright; Provisional patent. Z.S. Buchwald: None. W.A. Stokes: None. T. Nasti: None. J. Switchenko: None. B.D. Weinberg: None. N. Rouphael: None. J.P. Steinberg: None. K.D. Godette: None. D.J. Murphy: None. R. Ahmed: None. W.J. Curran: None. M.K. Khan: Patent/License Fees/Copyright; Provisional patent.
Research Categories
  • Biology, Radiation
  • Health Sciences, Immunology

Tools

Relations

In Collection:

Items

Thumbnail Title File Description Date Uploaded Visibility Actions
file details Publication File - vsw4p.pdf Primary Content 2025-05-05 Public Download